Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells.

Oldham, E. A.; Li, Chun; Shi, Ke; Wallace, Sidney; Huang, Peng

doi:10.3892/ijo.16.1.125

Cited by 25 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, enhanced permeability and retention effect of PG-TXL are likely important contributing factors responsible for the superior therapeutic index of PG-TXL observed in preclinical studies. [16]. These results suggest that it was the free paclitaxel released into the culture media that had been taken up by the cells.…”

Section: Preclinical Pharmacology and Mechanism Of Actionmentioning

confidence: 59%

“…Morphological analysis and biochemical characterizations in a panel of breast cancer cell lines confirmed that both PG-TXL and paclitaxel had similar abilities to induce apoptosis, independent of p53 status. Flow cytometric analysis further revealed that both PG-TXL and the free drug induced a characteristic G2/M arrest in the cell cycle [16]. However, compared with paclitaxel, PG-TXL appears to have reduced potency in vitro.…”

Section: Preclinical Pharmacology and Mechanism Of Actionmentioning

confidence: 99%

See 1 more Smart Citation

Polymer-drug conjugates: Recent development in clinical oncology

Wallace

2008

Advanced Drug Delivery Reviews

398

237

View full text Add to dashboard Cite

Targeted drug delivery aims to increase the therapeutic index by making more drug molecules available at the diseased sites while reducing systemic drug exposure. In this update, we provide an overview of polymer-drug conjugates that have advanced into the clinical trials. These systems use synthetic water-soluble polymers as the drug carriers. The preclinical pharmacology and recent data in clinical trials with poly(L-glutamic acid)-paclitaxel (PG-TXL) are discussed first. This is followed by a summary of conjugates of a variety of polymeric conjugates with chemotherapeutic agents. Results from early clinical trials of these polymer-drug conjugates have demonstrated several advantages over the corresponding parent drugs, including fewer side effects, enhanced therapeutic efficacy, ease of drug administration, and improved patient compliance. Collectively, these data warrant further clinical development of polymer-drug conjugates as a new class of anticancer agents.

show abstract

Section: Preclinical Pharmacology and Mechanism Of Actionmentioning

confidence: 59%

Section: Preclinical Pharmacology and Mechanism Of Actionmentioning

confidence: 99%

Polymer-drug conjugates: Recent development in clinical oncology

Wallace

2008

Advanced Drug Delivery Reviews

398

237

View full text Add to dashboard Cite

show abstract

“…Fulvestrant induced BIK mRNA far more strongly than doxorubicin after 42-hour exposure. In contrast, paclitaxel, a chemotherapeutic agent that induces apoptosis of breast cancer cells in a manner independent of their p53 status (29), also induced MCF7 cell apoptosis but without inducing BIK mRNA expression. Therefore, the induction of the BIK mRNA is not a nonspecific consequence of activation of the apoptotic pathway.…”

Section: Resultsmentioning

confidence: 99%

Regulation of Expression of BIK Proapoptotic Protein in Human Breast Cancer Cells: p53-Dependent Induction of BIK mRNA by Fulvestrant and Proteasomal Degradation of BIK Protein

Hur¹,

Bell

Dean³

et al. 2006

Cancer Research

View full text Add to dashboard Cite

Induction of mRNA for BIK proapoptotic protein by doxorubicin or ;-irradiation requires the DNA-binding transcription factor activity of p53. In MCF7 cells, pure antiestrogen fulvestrant also induces BIK mRNA and apoptosis. Here, we provide evidence that, in contrast to doxorubicin or ;-irradiation, fulvestrant induction of BIK mRNA is not a direct effect of the transcriptional activity of p53, although p53 is necessary for this induction. It is known that p53 up-regulated modulator of apoptosis (PUMA) mRNA is induced directly by the transcriptional activity of p53. Whereas ;-irradiation induced both BIK and PUMA mRNA, only BIK mRNA was induced by fulvestrant. Whereas both fulvestrant and doxorubicin induced BIK mRNA, only doxorubicin enhanced the DNA-binding activity of p53 and induced PUMA mRNA. Small interfering RNA (siRNA) suppression of p53 expression as well as overexpression of dominant-negative p53 effectively inhibited the fulvestrant induction of BIK mRNA, protein, and apoptosis. Transcriptional activity of a 2-kb BIK promoter, which contained an incomplete p53-binding sequence, was not affected by fulvestrant when tested by reporter assay. Fulvestrant neither affected the stability of the BIK mRNA transcripts. Interestingly, other human breast cancer cells, such as ZR75-1, constitutively expressed BIK mRNA even without fulvestrant. In these cells, however, BIK protein seemed to be rapidly degraded by proteasome, and siRNA suppression of BIK in ZR75-1 cells inhibited apoptosis induced by MG132 proteasome inhibitor. These results suggest that expression of BIK in human breast cancer cells is regulated at the mRNA level by a mechanism involving a nontranscriptional activity of p53 and by proteasomal degradation of BIK protein. (Cancer Res 2006; 66(20): 10153-61)

show abstract

“…Over a dozen NP platforms based on liposomes [26][27][28][29][30][31][32], albumin [33][34][35][36][37], polymeric micelles [38][39][40][41], and nanosized polymer-drug conjugates [42][43][44][45] have been ratified by the FDA (Table 1). A few targeted NPs including Her2 scFvtargeted liposomes (MM-302) [46], the first targeted controlled-release polymeric NP BIND-014 [47], and the first targeted short interfering (si) RNA NP CALAA-01 [48] are currently being tested in clinical trials for cancer therapy.…”

Section: Major Diseases Leading To Kidney Failurementioning

confidence: 99%

A mini review highlights on the application of nano-materials for Kidney disease: A key development in Medicinal therapy

Rahman¹,

Likius²,

Uahengo³

et al. 2017

Nephrol Renal Dis

View full text Add to dashboard Cite

Nanoparticles have been one of the emerging tools in medical field as a technology well-suited for the diagnosis and treatment of various diseases. They have been heralded as efficacious owing to both in terms of improved therapeutic efficacy as well as reduction of treatment side effects in some cases. Various nanomaterials have been developed which can be tagged with targeting moieties, and with drug delivery and imaging capability or combination of both as theranostic agent.Biotechnology to a large extent relies greatly on biomolecules such as proteins and DNA. Research in the field of bio technology will undeniably profit with the initiation of chemical and materials synthesis (e.g. multifunctional nanoparticle systems) that allows fusion of these biomolecules to nanostructured inorganic and organic materials. These nanomaterials have been thoroughly investigated for treatment and detection of various pathological conditions. This mini review highlights, the shape, size of nanoparticles to demonstrate the current research and applications of nanoparticles in the treatment of kidney diseases.

show abstract

Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells.

Cited by 25 publications

References 0 publications

Polymer-drug conjugates: Recent development in clinical oncology

Polymer-drug conjugates: Recent development in clinical oncology

Regulation of Expression of BIK Proapoptotic Protein in Human Breast Cancer Cells: p53-Dependent Induction of BIK mRNA by Fulvestrant and Proteasomal Degradation of BIK Protein

A mini review highlights on the application of nano-materials for Kidney disease: A key development in Medicinal therapy

Contact Info

Product

Resources

About